Author:
Zhang Hui,Zaric Gregory S.
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Reference40 articles.
1. Taylor, R., Drummond, M., Salkeld, G., Sullivan, S.: Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329(7472), 972–975 (2004)
2. Radley, D.C., Finkelstein, S.N., Stafford, R.S.: Off-label prescribing among office-based physicians. Arch. Intern. Med. 166, 1021–1026 (2006)
3. Tabarrok, A.T.: Assessing the FDA via the anomaly of off-label drug prescribing. Indep. Rev., V(1), 25–53 (2000)
4. Coyle, D., Buxton, M.J., O’Brien, B.J.: Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Econ. 12, 421–427 (2003)
5. The New York Times: Pfizer to pay $430 million over promoting drug to doctors (2004). http://query.nytimes.com/gst/fullpage.html?res=9400EEDC1F3CF937A25756C0A9629C8B63&sec=&spon=&pagewanted=all . Accessed 25 Nov 2008
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献